Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

Share Price is delayed by 15 minutes
Get Live Data
8.50    0.00 (0.00%)
Bid:
8.00
Ask:
9.00
Spread: 1.00 (12.50%)
Market Cap: £538.27m
AGY Live PriceLast checked at - London Stock Exchange

Intraday Allergy Thera. Share Chart

Grant of Options

19 Dec 2012 15:14

RNS Number : 9500T
Allergy Therapeutics PLC
19 December 2012
 



19 December 2012

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

 

 

Grant of Options

 

Allergy Therapeutics plc (AIM: AGY) announces that, pursuant to the Allergy Therapeutics plc Long Term Share Incentive Plan ('LTIP'), on 19 December 2012 provisional shares of 0.1 pence each in the share capital of the Company were awarded to the following Board Directors, Mr Manuel Llobet (Chief Executive Officer) and Mr Ian Postlethwaite (Finance Director) at nil cost, as follows:

 

Director

Number of provisional shares awarded

Date of distribution

Total provisional shares held under LTIPs

Manuel Llobet

720,000

19 December 2012

2,160,000

Ian Postlethwaite

360,000

19 December 2012

1,080,000

 

 

The issuance and distribution of ordinary shares of 0.1 pence each under the LTIP is conditional on the Company's performance over the course of the three years ending 30 June 2015.

 

-Ends-

 

For further information

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nomura Code Securities

+44 (0) 207 776 1200

Juliet Thompson/ Clare Terlouw

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSBUBDDDBBBGDC
Date   Source Headline
2nd Sep 20224:50 pmRNSTotal Voting Rights
2nd Aug 202212:58 pmRNSBlock Listing Interim Review
15th Jul 20227:00 amRNSTrading Update and Notice of Results
1st Jul 20227:00 amRNSAllergy Therapeutics at EAACI Congress 2022
26th May 20227:00 amRNSNick Wykeman to step down as CFO
23rd May 20227:00 amRNSAllergy Therapeutics at H.C. Wainwright Conference
25th Apr 20227:00 amRNSAllergy Therapeutics shares data at WAO-BSACI
7th Mar 20227:00 amRNSAllergy Therapeutics at Investor Meet Company
3rd Mar 20227:00 amRNSAllergy Therapeutics plc – Interim Results
1st Mar 20227:00 amRNSAllergy Therapeutics shares positive new data
24th Feb 20224:41 pmRNSSecond Price Monitoring Extn
24th Feb 20224:36 pmRNSPrice Monitoring Extension
24th Feb 20222:06 pmRNSSecond Price Monitoring Extn
24th Feb 20222:01 pmRNSPrice Monitoring Extension
2nd Feb 202211:05 amRNSSecures new revolving credit facility
1st Feb 20222:16 pmRNSTotal Voting Rights
26th Jan 20227:00 amRNSFDA clearance of IND application for VLP Peanut
24th Jan 20221:13 pmRNSHolding(s) in Company
13th Jan 20227:00 amRNSHalf Year Trading Update & Notice of Results
5th Jan 20228:47 amRNSTotal Voting Rights
25th Nov 20219:17 amRNSAllergy Therapeutics: Granting of Awards
23rd Nov 202112:54 pmRNSResult of AGM
11th Nov 20217:00 amRNSDirector Dealings
27th Oct 20217:00 amRNSCheryl MacDiarmid appointed to Board of Directors
25th Oct 20219:00 amRNSPrice Monitoring Extension
14th Oct 20219:24 amRNSHolding(s) in Company
7th Oct 20214:37 pmRNSAnnual Report and AGM Notification
23rd Sep 20217:00 amRNSPreliminary Results for Year ended 30 June 2021
16th Sep 20217:00 amRNSImmunoBON voted Most Innovative Product of 2021
13th Sep 20217:00 amRNSSecondary endpoints from VLP Peanut 001
9th Sep 20217:00 amRNSAllergy to Present at H.C. Wainwright Conference
7th Sep 20217:00 amRNSAllergy to host KOL webinar on VLP Peanut
3rd Aug 20217:00 amRNSSuccessful primary outcome of VLP Peanut 001
2nd Aug 202110:57 amRNSTotal Voting Rights
14th Jul 20217:00 amRNSTrading update for the year ended 30 June 2021
8th Jul 20217:00 amRNSAGY to present key scientific findings at EAACI
24th Jun 20217:00 amRNSTrading Update
1st Jun 20213:36 pmRNSTotal Voting Rights
10th May 20212:06 pmRNSSecond Price Monitoring Extn
10th May 20212:00 pmRNSPrice Monitoring Extension
6th May 20217:00 amRNSCompletion of treatment phase in G309 study
30th Apr 20215:47 pmRNSTotal Voting Rights
16th Apr 20217:00 amRNSAppointment of new Group auditors
31st Mar 20218:29 amRNSVesting of Awards under Long Term Incentive Plan
26th Mar 20214:39 pmRNSPledge of Shares
11th Mar 202112:13 pmRNSPledge of Shares
10th Mar 20214:40 pmRNSSecond Price Monitoring Extn
10th Mar 20214:35 pmRNSPrice Monitoring Extension
10th Mar 20212:05 pmRNSSecond Price Monitoring Extn
10th Mar 20212:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.